Generelt synes jeg informasjon om bĂ„de salgsmilepĂŠlene og royaltysatsene kunne vĂŠrt noe mer utfyllende - men jeg har ogsĂ„ forstĂ„tt at dersom Cevira blir en blockbuster, vil alle engangsutbetalingene utlĂžses - og i snitt vil royaltysatsen vĂŠre hĂžyere enn 10 % ved salg opp til 1 mrd USD. Men selv med 10 % snakker vi om royalty pĂ„ ca. 1 mrd NOKâŠDa er ikke skatten vĂ„rt stĂžrste problem:)
1 Like
Hanselsbanken ute med sin Results Preview i dag : Awaiting the growth inflection
Reiterating NOK 120 target price and Outperform/Buy recommendations
https://reonapi.researchonline.se/f/hero_vAqWl-5EPttgHu-Zs1KW7lF4yg-bEPL39Ak1v0PRGgw
15 Likes
Da virker det lite rasjonelt Ă„ selge for 52,5. Men det er det man gjĂžr.
1 Like
Tre-Ärs target price. Folk mÄ fÄ lov til Ä disponere sine aksjebeholdninger som de vil.
1 Like
H2 2025 og launch 2026 tror jeg bare er en âplaceholderâ da det er ingen som vet nĂ„r det blir godkjent.
Tar man âworst caseâ scenario pĂ„ hvor lang tid det tar Ă„ fĂ„ godkjent noe i Kina sĂ„ havner man pĂ„ H2. Som da blir en naturlig tidspunkt Ă„ putte i en analyse.
Ikke vits i Ä spekulere sÄ mye. Ting skjer nÄr det skjer.
The R&D Open Day was successfully held, and the unmet clinical needs of specialization and value-driven were successfully held
Oct 24, 2024/Press release
Shanghai, China, October 24, 2024 â STAR Market-listed Yahong Pharma (688176. SH) held its 2024 R&D Open Day in Shanghai on October 22 with the theme of âSpecialized Value, Science and Technology for the Futureâ, with more than 30 institutional personnel participating.
Dr. Pan Ke, Founder, Chairman and CEO of Yahong Pharmaceutical, mentioned at the companyâs R&D Open Day, "Innovation is the only secret to overcoming involution and grasping the opportunities of the rapid development of Chinaâs pharmaceutical market. â
Dr. Pan Ke said that Yahong Pharma is a global specialty innovative drug company focusing on genitourinary tumors and womenâs health. As of the end of the first half of the year, the companyâs main product pipeline has 13 products and 18 projects under development, of which APL-1706 (developer) and APL-1702 (photodynamic drug-device combination product) are two products with rapid R&D progress.
Dr. Pan Ke, Founder, Chairman and CEO of Yahong Pharmaceutical
The companyâs R&D strategy: differentiation, integration of diagnosis and treatment, best-in-class
In the future, homogeneous products will gradually lose their competitiveness, and the development ability of FIC/BIC drugs will become the core competitiveness of innovative pharmaceutical companies. Dr. Wu Liang, Senior Director of Pharmaceutical Chemistry of Yahong Pharmaceutical, said that the small molecule R&D of BIC of Yahong Pharma focuses on the field of diseases, clinical needs, target research, and molecular design, so as to make the products more differentiated and competitive. At the same time, the company has upgraded its next-generation targeted and AI-driven drug discovery platform, which can reduce the time and resources required for drug discovery and development compared with traditional drug development, accelerate the research and development process, and improve product competitiveness.
Drug-device combination products use drug delivery technology to deliver diagnostic or therapeutic drugs to the target site, reduce the systemic exposure of drugs, and improve the diagnosis/treatment effect of drugs while improving safety. This kind of product is a feature of Yahong Pharmaceutical, which explores the direction of the companyâs integrated diagnosis and treatment strategy. Dr. Huang Guofeng, head of Yahong Pharmaceuticalâs drug-device platform, said that the portable disposable diagnostic flexible scope developed by the company is expected to fill the gap in this field, and the development technology being developed with faster imaging speed and higher sensitivity can further improve adaptability, improve the diagnostic efficiency of hospitals/clinics, and benefit patients and the medical system.
ADC drugs are one of the hot research directions in the field of tumor treatment because of the high specificity of antibodies and the high anti-tumor activity of cytotoxins, and the safety is more controllable. The global ADC drug market is expected to grow at a rate of approximately 15% from 2023 to 2028. Dr. Yu Chen, Senior Vice President of Biological Research of the New Drug Discovery Department of Yahong Pharma, said that the companyâs ADC team is committed to driving innovation in the field of antibody drug conjugates (ADCs) and developing first-in-class or best-in-class cytotoxic antibody conjugates (ADCs) with proprietary ligation technology for novel or validated antibody targets. Yahong Pharma has established an advanced degradation antibody conjugation (DAC) platform and expects to position the company in the next wave of innovation in ADC payloads.
The scene of Yahong Pharmaceuticalâs 2024 R&D Open Day
Photodynamic therapy technology is used to meet the clinical needs of womenâs health
The cause of cervical cancer is clear, mainly caused by persistent HPV (human papillomavirus) infection, and at the same time, the progression from HPV infection to invasive cervical cancer is a long process, so cervical cancer is completely preventable, that is, through tertiary prevention measures, that is, HPV vaccination for young women, cervical cancer screening in women of appropriate age, timely treatment of precancerous lesions and cervical cancer, can effectively prevent and control and ultimately achieve the elimination of cervical cancer.
âWith the vigorous development of cervical cancer screening in China in recent years, more and more cervical precancerous lesions have been detected early, and the population is large and younger, which has brought new challenges to the treatment of cervical precancerous lesions in women of childbearing age who are in the important window period of âfertility protectionâ in the context of declining fertility rate,â said Professor Sui Long, professor of the Obstetrics and Gynecology Hospital of Fudan University, director of the Cervical Disease Diagnosis and Treatment Center, and vice chairman of the CSCCP. Invasive cervical resectional surgery has long been a classic method for the treatment of cervical precancerous lesions, but it cannot meet all clinical treatment needs, due to the potential adverse effects of postoperative complications on womenâs future fertility, such as preterm birth and miscarriage; Second, recurrence is still possible after treatment, which must be managed for a long time, but a larger range of cervical resection surgery may cause changes in cervical morphology, increase the risk of missed diagnosis in postoperative colposcopy follow-up, and then increase the difficulty of long-term management. Therefore, both doctors and patients are looking forward to the early approval of effective and safe non-invasive treatments to help suitable female patients avoid or delay cervical trauma. â
Professor Wang Xiuli, professor of Tongji University Dermatology Hospital/Shanghai Dermatology Hospital, director of the Institute of Photomedicine of Tongji University School of Medicine, and executive director of the International Photodynamic Association, introduced at the meeting that photodynamic therapy (PDT) can selectively destroy diseased tissues, cause slight damage to normal tissues, and will not cause scarring, while recovery is fast, adverse reactions are few, and reproducible treatment is possible. Moreover, in addition to clearing the lesion, it can also stimulate local immunity, which is a unique advantage in the mechanism of photodynamic therapy. With the development of photosensitizer and light source technology, PDT has been widely used and has been used for the diagnosis and treatment of diseases in multiple tissues and organs, including cancer. The new photodynamic cervical treatment system developed by Yahong Pharma uses a fat-soluble local photosensitizer HAL to increase the absorption rate of tissue cells, and an innovative low-temperature light source to improve patient comfort and tolerance.
APL-1702 is the worldâs first non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix, which is expected to be the worldâs first and Chinaâs first innovative non-invasive treatment of cervical precancerous lesions. He Xiaoting, deputy medical director of Yahong Pharmaceutical, said that the product is the worldâs first HSIL treatment product to obtain positive results in an international multi-center phase III clinical trial, and the results confirm that it has significant efficacy and good safety. At the same time, it is easy to operate, and after placement, patients can leave the hospital without waiting. In September this year, the clinical trial results were successively selected into the International Conference on Photodynamics and Photodiagnostics (PDT&PD) and the 27th National Congress of Clinical Oncology (CSCO) Academic Annual Meeting, which attracted great attention from the academic community and reflected the huge clinical demand and social value of APL-1702.
Focus on the field of genitourinary tumors, focusing on unmet clinical needs
Professor Hu Hailong, the leader of the bladder cancer discipline in the Department of Urology of the Second Hospital of Tianjin Medical University, said that transurethral bladder tumor resection (TURBT) has certain limitations, high recurrence rate after surgery, and the risk of NMIBC progressing to MIBC is high, the treatment is more difficult, and the prognosis of patients is poor. At the same time, postoperative recurrence of NMIBC patients will increase the financial burden of the family, aggravate the psychological pressure of patients, and seriously affect the quality of life, and there are multiple risk factors for postoperative recurrence in NMIBC patients. Compared with traditional white light cystoscopy, blue light cystoscopy has shown great advantages in both diagnosis and surgery, which can significantly improve the detection rate of bladder tumors and reduce the recurrence rate of residual tumors, thereby improving recurrence-free survival.
APL-1706 is currently the only approved contrast agent in the world to assist in the diagnosis or surgery of bladder cancer, and has been approved for marketing in more than 30 countries around the world. The combination of this product and blue light cystoscopy can effectively improve the detection rate of NMIBC (especially the detection rate of carcinoma in situ), make the resection operation more complete, and thus reduce the tumor recurrence rate. There are currently no approved drugs of this kind in China, and the approval of APL-1706 will fill this gap and solve the problem of no drug available for guideline recommendation at this stage.
APL-1202 is the first-in-class oral and reversible MetAP2 inhibitor in Phase III clinical development. On September 26, the phase II clinical trial of APL-1202 and PD-1 inhibitor tislelizumab in combination with neoadjuvant treatment of muscle-invasive bladder cancer (MIBC) achieved positive efficacy. Baddrinath Konety, MD, director and chief research officer of the Allina Health Cancer Institute, professor of urology at Rush School of Medicine, and former president of the International Urological Society SIU, said that in the population with a baseline diagnosis of MIBC diagnosed by central pathology (modified evaluable analysis set, mEAS), APL-1202 was 41% (9/22) in the combination treatment arm with tislelizumab compared with 20% pCR in the tslelizumab monotherapy group (4/ 20), doubling, showing acceptable safety profiles. APL-1202+PD-1 is competitive in terms of efficacy/safety/dose friendliness.
In addition, based on the TAIDD platform, the company has independently researched and developed a new highly selective and potent ubiquitin-specific protease 1 (USP1) oral small molecule inhibitor APL-2302. Wang Zijia, deputy medical director of Yahong Pharmaceutical, said that preclinical studies have shown that APL-2302 monotherapy and combination therapy have shown good in vitro and in vivo activity in tumor suppression. APL-2302 has the potential to be a new option for the treatment of advanced solid tumors (breast, ovarian, prostate, etc.) that are positive for specific biomarkers (e.g., BRCA gene mutations, etc.).
11 Likes
Vanvittig hĂžy omsetning i dag â Frem til 14:00 er det omsatt hele 4083 aksjer 
3 Likes
Forunderlig at aksjer lempes villig ut pÄ dette nivÄet. 
1 Like
At det var hele 3 Ärs horisont sÄ jeg ikke. Men forutsatt at man ikke tenker at kursen fÞrst gÄr om tre Är, men beveger seg gradvis mot 120, sÄ vil det si ca 75 om et Är og 95 om to Är, sett bort ifra traderherjinger.
Ikke kursmÄl til Ä bli yr av akkurat, men ok.
Norne hadde kursmÄl kr 120 allerede i 2022, etter at den toppet pÄ rundt 150 ett Är tidligere.
Siden er kursmÄlene redusert i takt med stupende kurs.
Noe har skjedd med verdiforventningene tiltross for at mye usikkerhet er borte. Er det bare mer edruelighet blant investorer og analytikere som er grunnen?
Skal vi fÄ noe igjen for investeringen i Photocure mÄ vi hÄpe pÄ at noen vil kjÞpe opp selskapet. Gjerne budkamp.
Ser at Nekkar kjÞper sine egne aksjer. Buy Back program ville gagne Photocure pÄ flere plan.
I det minste, gjÞr noe! VÊrt dead duck altfor lenge, slik at det er det inntrykket investorer sitter igjen med. Lite aksjonÊrvennlig selskap med en ledelse som passer pÄ at de fÄr presset mest mulig ut av selskapet pÄ bekostning av aksjonÊrene. 
Vil heller at de begynner med litt utbytter framfor kjĂžp av aksje. De vil tiltrekke seg flere kjĂžpergrupper
4 Likes
Godt forslag. 
De som er investert i PHO mener selvfÞlgelig at dagens kurs er for lav - samtidig (for de som ser det utenfra) har kursutviklignen ikke vÊrt mye Ä skryte av. NÄr det er sagt, er jeg ogsÄ en av dem som synes det er merkelig at PHO ikke benytter anledningen til Ä skrive mer om bÄde potensialet og innholdet i Cevira avtalen - og bare venter pÄ at den sÄkalte FOMO effekten skal vise seg. Men det som i alle fall er sikkert, er at dersom Cevira godkjennes og blir i nÊrheten av den suksessen Aseris og andre har uttrykt, vil ikke kursen ligge pÄ 50 tallet.
6 Likes
Det som er fascinerende er at det nesten kun er Cevira avtalen det blir snakket om. Virker som alt annet er glemt her inne.
Husker nĂ„r Cevira avtalen ble kjent, var ikke mangen som sĂ„ den som noe annet en stĂžy. Totalt ukjent selskap, uten trackrecord, og ingen produkter i markedet. Enkelte tvilte pĂ„ om det i hele tatt ville komme noen milestone-betalingerâŠ
Selv etter de fĂžrste betalingene var skepsisen hĂžy.
Men som sagt, ser ut til at man har glemt:
Nye skop fra Olympus ( Venter pÄ godkjenning, noe som vil ha innvirkning pÄ norden)
Nedklassifisering fra USA (Venter pÄ svar)
Bli ferdig med utfasing av gamle flex skop. (Slik at nye skop faktisk gir vekst og ikke bare kompenserer for bortfallet i USA)
Hexvix godkjenning i Kina.
Noe jeg har glemt i farten?
20 Likes
Nyutviklede flex skop ferdigutviklet om et par Ă„r.
1 Like
Det er kanskje ikke sÄ rart at det er mye fokus pÄ Cevira, nÄ som vi er straks pÄ opplÞpssiden - men du har helt rett, PHO er i en unik situasjon ved at en faktisk har flere bein Ä stÄ pÄ.
2 Likes
Thor medical skyter opp pÄ en avtale verdt ca 17 mill dollar over 5 Är. PHO sin milepÊl ved godkjennelse i kina er vel rundt 17 millioner dollar?
1 Like
Photocure is eligible for a USD 11.0 million milestone payment for the potential regulatory approval of Cevira in China
1 Like
Da vil vel PHO begynne Ä nÊrme seg en halv milliard pÄ konto, pÄ tide at noe tilgodeses aksjonÊrene tenker jeg, mens vi venter pÄ royalties.
2 Likes